Brokers Issue Forecasts for Sanofi FY2024 Earnings

Sanofi (NASDAQ:SNY) – Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for shares of Sanofi in a research note issued to investors on Monday, January 27th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings per share of $3.77 for the year. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.75 EPS, Q2 2025 earnings at $0.84 EPS, FY2025 earnings at $4.06 EPS, FY2026 earnings at $4.57 EPS, FY2027 earnings at $4.76 EPS and FY2028 earnings at $5.39 EPS.

A number of other brokerages also recently weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Sanofi Trading Up 0.4 %

NASDAQ SNY opened at $54.34 on Thursday. The firm’s 50 day moving average price is $49.24 and its two-hundred day moving average price is $52.27. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a market cap of $137.91 billion, a price-to-earnings ratio of 27.72, a PEG ratio of 1.21 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Northwest Investment Counselors LLC bought a new position in shares of Sanofi in the third quarter worth about $29,000. Synergy Asset Management LLC acquired a new position in shares of Sanofi during the fourth quarter valued at about $25,000. Concord Wealth Partners lifted its stake in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares during the period. McClarren Financial Advisors Inc. increased its stake in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Finally, Sunbelt Securities Inc. raised its holdings in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.